RecruitingNCT07402577
Brief Title Mechanisms of Cancer-Related Pain and Opioid Use Among Adolescents and Young Adult Sarcoma Survivors: Pilot Feasibility Study
Sponsor
Roswell Park Cancer Institute
Enrollment
40 participants
Start Date
Mar 30, 2026
Study Type
OBSERVATIONAL
Conditions
Summary
This study generates information on the feasibility and acceptability of a 3-month ecological momentary assessment (EMA) protocol to assess chronic pain and opioid use in adolescent and young adult (AYA) sarcoma survivors.
Eligibility
Min Age: 12 YearsMax Age: 70 Years
Plain Language Summary
Simplified for easier understanding
This study is trying to understand why some young cancer survivors experience chronic pain after being treated for sarcoma (bone or soft tissue cancer), and how opioid pain medications affect them. It is a pilot study focused on teens and young adults.
**You may be eligible if...**
- You were diagnosed with sarcoma between ages 12 and 24
- You are currently under 70 years old and enrolled in survivorship care
- Your cancer is currently showing no signs of active disease
- You have meaningful ongoing pain (rated 3 or higher on a 0–10 scale) related to your cancer or treatment
- You have a smartphone with internet access
**You may NOT be eligible if...**
- You are currently receiving active cancer treatment
- You are unable to read or speak English fluently
- You cannot complete assessments on your phone over a 3-month period
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERNon Intervention Study
Non intervention study
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07402577
Related Trials
Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies
NCT011093945 locations
Combination Immunotherapy Targeting Sarcomas
NCT044332211 location
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
NCT023907521 location
Locally ablatiVe therApy in oLigO-pRogressive sOlid tUmorS (VALOROUS)
NCT061036691 location
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
NCT0678917210 locations